GlassScriptPhysician profile
Caren Rose Nituda
NPI 1447857222
$1,339.07
in general payments reported to CMS, 2019-2025
19 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $152 · 2022: $87.73 · 2023: $235 · 2024: $416 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.58 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $386.11 | 2021-2025 | Rybrevant, Darzalex, Tecvayli |
| Incyte Corporation | $220.52 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $105.07 | 2022-2025 | Injectafer, Enhertu |
| Astellas Pharma US INC | $99.95 | 2025 | |
| Genentech USA, INC. | $84.20 | 2023-2025 | Polivy, Lunsumio, Gazyva |
| Pharmacosmos Therapeutics INC. | $75.01 | 2023 | Monoferric |
| Celgene Corporation | $60.41 | 2023-2024 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $45.14 | 2021-2025 | |
| Coherus Oncology, INC. | $36.73 | 2024 | |
| Amgen INC. | $29.53 | 2022 | |
| Geron Corporation | $28.23 | 2025 | Rytelo |
| Abbvie INC. | $25.55 | 2023 | |
| Dendreon Pharmaceuticals LLC | $25.24 | 2025 | Provenge |
| Tersera Therapeutics LLC | $22.84 | 2025 | Zoladex |
| Grifols USA, LLC | $22.28 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $21.99 | 2024 | Iclusig |
| Alexion Pharmaceuticals, INC. | $18.29 | 2025 | Ultomiris |
| Pfizer INC. | $18.18 | 2021 | |
| Genzyme Corporation | $13.80 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caren Nituda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.